272 related articles for article (PubMed ID: 19584240)
21. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
23. Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells.
Xu C; Shen G; Chen C; GĂ©linas C; Kong AN
Oncogene; 2005 Jun; 24(28):4486-95. PubMed ID: 15856023
[TBL] [Abstract][Full Text] [Related]
24. 2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways.
Shah S; Hess-Wilson JK; Webb S; Daly H; Godoy-Tundidor S; Kim J; Boldison J; Daaka Y; Knudsen KE
Mol Cancer Res; 2008 Sep; 6(9):1507-20. PubMed ID: 18819937
[TBL] [Abstract][Full Text] [Related]
25. Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
Tsui KH; Chang YL; Feng TH; Hou CP; Lin YH; Yang PS; Lee BW; Juang HH
Prostate; 2018 Mar; 78(4):242-249. PubMed ID: 29164633
[TBL] [Abstract][Full Text] [Related]
26. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S
Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608
[TBL] [Abstract][Full Text] [Related]
27. [Expression and regulation of androgen receptor in the androgen-independent conversion of prostate cancer cells].
Wang HF; Liu WJ; Jin J; Zhou LQ; Liang LL; Wang Y; Guo YL
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Aug; 43(4):490-5. PubMed ID: 21844951
[TBL] [Abstract][Full Text] [Related]
28. Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention.
Wang L; Liu D; Ahmed T; Chung FL; Conaway C; Chiao JW
Int J Oncol; 2004 Jan; 24(1):187-92. PubMed ID: 14654956
[TBL] [Abstract][Full Text] [Related]
29. Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells.
He ML; Yuan HQ; Jiang AL; Gong AY; Chen WW; Zhang PJ; Young CY; Zhang JY
Cancer; 2006 Jun; 106(12):2547-55. PubMed ID: 16691616
[TBL] [Abstract][Full Text] [Related]
30. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
[TBL] [Abstract][Full Text] [Related]
31. Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits.
Vyas AR; Moura MB; Hahm ER; Singh KB; Singh SV
J Cell Biochem; 2016 Nov; 117(11):2482-95. PubMed ID: 26990292
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells.
Pinto JT; Sinha R; Papp K; Facompre ND; Desai D; El-Bayoumy K
Int J Cancer; 2007 Apr; 120(7):1410-7. PubMed ID: 17205524
[TBL] [Abstract][Full Text] [Related]
33. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
34. A novel class of pyranocoumarin anti-androgen receptor signaling compounds.
Guo J; Jiang C; Wang Z; Lee HJ; Hu H; Malewicz B; Lee HJ; Lee JH; Baek NI; Jeong JH; Kim DK; Kang KS; Kim SH; Lu J
Mol Cancer Ther; 2007 Mar; 6(3):907-17. PubMed ID: 17363485
[TBL] [Abstract][Full Text] [Related]
35. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6.
Gibbs A; Schwartzman J; Deng V; Alumkal J
Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16663-8. PubMed ID: 19805354
[TBL] [Abstract][Full Text] [Related]
36. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
37. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.
Saporita AJ; Ai J; Wang Z
Prostate; 2007 Apr; 67(5):509-20. PubMed ID: 17221841
[TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
[TBL] [Abstract][Full Text] [Related]
39. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
Abdelbaqi K; Lack N; Guns ET; Kotha L; Safe S; Sanderson JT
Prostate; 2011 Sep; 71(13):1401-12. PubMed ID: 21321979
[TBL] [Abstract][Full Text] [Related]
40. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]